Reduction of ischemic events after 30 months of prasugrel following TAXUS stent implantation

Article

The TAXUS Liberté Post Approval study included patients treated with TAXUS paclitaxel DES receiving prasugrel for 12 to 30 months. Primary end point was a combination of death, infarction or stroke that resulted in 3.7% after 30 months vs. 8.8% after 12 months of prasugrel administration (p<0.001).

Death and stroke rates were similar between the two groups but the infarction rate saw a  significant reduction after prolonged double antiaggregation therapy with aspirin and prasugrel (1.9% vs 7.1%; p<0,001).

In stent thrombosis was also lower after prolonged therapy (0.2% vs 2.9%; p<0,001). Infarction rate was higher within 90 days after prasugrel withdrawal in both groups.

Safety end point (a combination of moderate and severe bleeding) was slightly higher in the 30 month group (2.4% vs 1.7%; p= 0,234) but looking at severe bleeding alone, rates saw no significant difference (0.3% vs 0.5%; p=0,471).

Conclusion

The combined administration of prasugrel and aspirin at 30 months reduced ischemic events rates in patients receiving TAXUS mainly due to reduced rates of infarction and in stent thrombosis, compared to the 12 month treatment.

3_kirk_garratt_presentacion
Kirk N Garratt
2014-11-17

Original title: Increased Risk of Ischemic Events Upon Discontinuation of Prasugrel After 12 or 30 Months of Therapy Following Placement of the Taxus Liberté Paclitaxel- Eluting Coronary Stent.

More articles by this author

Improved survival after out-of-hospital cardiac arrest with the use of automated external defibrillators

This study included patients presenting out of hospital cardiac arrest between 2006 and 2012 in The Netherlands to assess the impact of automated external...

Coronary flow reserve is associated to adverse events regardless angiographic severity.

This study included 329 consecutive patients derived to coronary angiography based on myocardial perfusion tests or PET scan (positron emission tomography). The extension and...

ITALIC PLUS: 6 months of double antiaggregation for no less than 24 months

Article This multicenter study included patients receiving the second generation stent XIENCE V (Abbott Vascular) randomized to 6 and 24 months of double antiaggregation therapy...

DAPT TRIAL: double antiaggregation remains controversial

Article This multicenter randomized control study with placebo was designed to determine the risks and benefits of double antiaggregation for longer than 12 months post...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...